Cargando…
Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection
BACKGROUND/AIMS: In an investigator-initiated, prospective study, we evaluated the feasibility of a five-gene sequence point-of-care (POC) testing strategy (Xpert CARBA-R Assay, Cepheid Inc., Sunnyvale, CA, USA), compared to reference laboratory PCR (48 – 72 hours turnaround time, two gene sequence...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
© Georg Thieme Verlag KG
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766332/ https://www.ncbi.nlm.nih.gov/pubmed/29340299 http://dx.doi.org/10.1055/s-0043-122141 |
_version_ | 1783292350371463168 |
---|---|
author | Pannala, Rahul Baldwin, Bruce Aluru, Vijay Grys, Thomas E. Holmes, Jordan Miller, Laurence J. Harrison, M. Edwyn Nguyen, Cuong C. Tenover, Fred C. Persing, David Faigel, Douglas O. |
author_facet | Pannala, Rahul Baldwin, Bruce Aluru, Vijay Grys, Thomas E. Holmes, Jordan Miller, Laurence J. Harrison, M. Edwyn Nguyen, Cuong C. Tenover, Fred C. Persing, David Faigel, Douglas O. |
author_sort | Pannala, Rahul |
collection | PubMed |
description | BACKGROUND/AIMS: In an investigator-initiated, prospective study, we evaluated the feasibility of a five-gene sequence point-of-care (POC) testing strategy (Xpert CARBA-R Assay, Cepheid Inc., Sunnyvale, CA, USA), compared to reference laboratory PCR (48 – 72 hours turnaround time, two gene sequences), in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) and in a hospital outbreak investigation. METHODS: After informed consent, patients undergoing ERCP (September 2015 – April 2016, n = 191) at Mayo Clinic and potential hospital contacts (n = 9) of an index carbapenem-resistant organism (CRO)-positive inpatient were included. Two rectal swabs, one each for reference and POC assays were obtained. The Xpert CARBA-R Assay enables qualitative rapid detection of five beta-lactamase gene sequences associated with carbapenem-non-susceptibility in Gram-negative bacteria. Feasibility parameters (specimen processing and assay run time, ease of use) and percent agreement between the tests were calculated using JMP Pro11 (SAS Corp, Cary, NC, USA). RESULTS: Mean age was 62 ± 15 years; 108 (54 %) were male. Both tests were successfully performed in all patients. The POC test was rated by endoscopy nurses as easy/very easy to conduct in 193 patients (97 %); median assay run time and median time for specimen collection and processing were 55 minutes (interquartile range IQR: 53 – 55 minutes) and 3 minutes (IQR: 3 – 6 minutes), respectively. In 200/201 (99.5 %) tests, there was agreement between the POC and reference PCR. CONCLUSIONS: The more comprehensive POC CRO testing of patients in the endoscopy suite is feasible and results are available in < 1 hour. This strategy may enable rapid risk stratification of duodenoscope exposure to CRO and potentially improve operational efficiency and decrease costs. |
format | Online Article Text |
id | pubmed-5766332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | © Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-57663322018-01-16 Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection Pannala, Rahul Baldwin, Bruce Aluru, Vijay Grys, Thomas E. Holmes, Jordan Miller, Laurence J. Harrison, M. Edwyn Nguyen, Cuong C. Tenover, Fred C. Persing, David Faigel, Douglas O. Endosc Int Open BACKGROUND/AIMS: In an investigator-initiated, prospective study, we evaluated the feasibility of a five-gene sequence point-of-care (POC) testing strategy (Xpert CARBA-R Assay, Cepheid Inc., Sunnyvale, CA, USA), compared to reference laboratory PCR (48 – 72 hours turnaround time, two gene sequences), in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) and in a hospital outbreak investigation. METHODS: After informed consent, patients undergoing ERCP (September 2015 – April 2016, n = 191) at Mayo Clinic and potential hospital contacts (n = 9) of an index carbapenem-resistant organism (CRO)-positive inpatient were included. Two rectal swabs, one each for reference and POC assays were obtained. The Xpert CARBA-R Assay enables qualitative rapid detection of five beta-lactamase gene sequences associated with carbapenem-non-susceptibility in Gram-negative bacteria. Feasibility parameters (specimen processing and assay run time, ease of use) and percent agreement between the tests were calculated using JMP Pro11 (SAS Corp, Cary, NC, USA). RESULTS: Mean age was 62 ± 15 years; 108 (54 %) were male. Both tests were successfully performed in all patients. The POC test was rated by endoscopy nurses as easy/very easy to conduct in 193 patients (97 %); median assay run time and median time for specimen collection and processing were 55 minutes (interquartile range IQR: 53 – 55 minutes) and 3 minutes (IQR: 3 – 6 minutes), respectively. In 200/201 (99.5 %) tests, there was agreement between the POC and reference PCR. CONCLUSIONS: The more comprehensive POC CRO testing of patients in the endoscopy suite is feasible and results are available in < 1 hour. This strategy may enable rapid risk stratification of duodenoscope exposure to CRO and potentially improve operational efficiency and decrease costs. © Georg Thieme Verlag KG 2018-01 2018-01-12 /pmc/articles/PMC5766332/ /pubmed/29340299 http://dx.doi.org/10.1055/s-0043-122141 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Pannala, Rahul Baldwin, Bruce Aluru, Vijay Grys, Thomas E. Holmes, Jordan Miller, Laurence J. Harrison, M. Edwyn Nguyen, Cuong C. Tenover, Fred C. Persing, David Faigel, Douglas O. Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection |
title | Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection |
title_full | Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection |
title_fullStr | Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection |
title_full_unstemmed | Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection |
title_short | Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection |
title_sort | prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766332/ https://www.ncbi.nlm.nih.gov/pubmed/29340299 http://dx.doi.org/10.1055/s-0043-122141 |
work_keys_str_mv | AT pannalarahul prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT baldwinbruce prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT aluruvijay prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT grysthomase prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT holmesjordan prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT millerlaurencej prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT harrisonmedwyn prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT nguyencuongc prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT tenoverfredc prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT persingdavid prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection AT faigeldouglaso prospectivestudyofthefeasibilityofpointofcaretestingstrategyforcarbapenemresistantorganismdetection |